Merck & Company is projected to report Q3 2026 revenue of approximately $17.31 billion and adjusted EPS of $2.12, while its current stock price of $145.27 sits below the average analyst price target of $159.26.
Investors are primarily focused on the sales trajectory of the oncology blockbuster Keytruda and the commercial ramp-up of new launches like Winrevair as the company prepares for its 2028 patent cliff.
Analysts are also watching for stability in Gardasil vaccine sales in China following recent demand concerns and legal challenges facing the new subcutaneous formulation. Recent headlines regarding a Phase 3 trial data leak for its mRNA cancer vaccine have added further scrutiny to management's pipeline updates.